At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...
Genetic medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three ...
The study was published in Nature Biotechnology last month and marks a shift in scientists’ understanding of how to ...
Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in ...
Researchers at University of Tsukuba have achieved high-resolution visualization of cellular organelles, such as nuclei and ...
Biomedical research typically follows a familiar path: developing treatments that block, enhance or mutate certain signaling pathways, genes or proteins to change the function of different cells in ...
Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% ...
A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...
Interest in lipid nanoparticles (LNPs) as delivery vehicles for precision therapies in genetic diseases and cancers remains at an all-time high. Now, scientists from the University of Pennsylvania, ...
In this article, data-dependent acquisition (DDA) experimental data collected by the ZenoTOF 8600 system was analyzed with MS-DIAL 5.5 software to detect and classify lipid molecular species in human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback